At a glance
ClinicalIndex Comparison RecordN/ACompleted· 158 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation - An Observational, Multi-Center Study
In Brief
An observational study for Chronic Hepatitis C and Genotype 1. Completed, enrolled 158 participants.
Detailed Summary
This study seeks to assess the effectiveness, patient reported outcomes, work productivity and healthcare resource utilization of the interferon-free regimen of paritaprevir /ritonavir (r) - ombitasvir, ± dasabuvir ± ribavirin (RBV) in participants with chronic hepatitis C in a real life setting across clinical practice populations.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C, Genotype 1
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartApr 2016
Primary CompletionJul 2017
TodayJul 2026
First PostedFeb 1, 2016
Enrollment StartApr 15, 2016
Primary CompletionJul 4, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.4 years ago